NasdaqGS - Nasdaq Real Time Price USD

Bruker Corporation (BRKR)

82.14 -0.32 (-0.39%)
As of 10:39 AM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,964,500.00
2,964,500.00
2,530,700.00
2,417,900.00
1,987,500.00
Cost of Revenue
1,451,200.00
1,451,200.00
1,225,000.00
1,208,300.00
1,047,700.00
Gross Profit
1,513,300.00
1,513,300.00
1,305,700.00
1,209,600.00
939,800.00
Operating Expense
1,029,900.00
1,029,900.00
849,700.00
788,100.00
678,300.00
Operating Income
483,400.00
483,400.00
456,000.00
421,500.00
261,500.00
Net Non Operating Interest Income Expense
-5,200.00
-5,200.00
-12,000.00
-13,400.00
-11,200.00
Other Income Expense
66,000.00
66,000.00
-30,100.00
-14,500.00
-24,500.00
Pretax Income
544,200.00
544,200.00
413,900.00
393,600.00
225,800.00
Tax Provision
117,700.00
117,700.00
116,400.00
113,000.00
64,400.00
Earnings from Equity Interest Net of Tax
2,000.00
2,000.00
1,000.00
--
--
Net Income Common Stockholders
427,200.00
427,200.00
296,600.00
277,100.00
157,800.00
Diluted NI Available to Com Stockholders
427,200.00
427,200.00
296,600.00
277,100.00
157,800.00
Basic EPS
2.92
2.92
2.00
1.83
1.03
Diluted EPS
2.90
2.90
1.99
1.81
1.02
Basic Average Shares
146,400.00
146,400.00
148,600.00
151,400.00
153,400.00
Diluted Average Shares
147,200.00
147,200.00
149,400.00
152,900.00
154,600.00
Total Operating Income as Reported
436,900.00
436,900.00
432,700.00
413,300.00
248,300.00
Total Expenses
2,481,100.00
2,481,100.00
2,074,700.00
1,996,400.00
1,726,000.00
Net Income from Continuing & Discontinued Operation
427,200.00
427,200.00
296,600.00
277,100.00
157,800.00
Normalized Income
371,300.80
371,300.80
317,666.70
287,438.50
175,317.50
Interest Income
11,200.00
11,200.00
4,100.00
900.00
3,200.00
Interest Expense
16,400.00
16,400.00
16,100.00
14,300.00
14,400.00
Net Interest Income
-5,200.00
-5,200.00
-12,000.00
-13,400.00
-11,200.00
EBIT
560,600.00
560,600.00
430,000.00
407,900.00
240,200.00
EBITDA
675,500.00
675,500.00
518,800.00
497,000.00
320,600.00
Reconciled Cost of Revenue
1,451,200.00
1,451,200.00
1,225,000.00
1,208,300.00
1,047,700.00
Reconciled Depreciation
114,900.00
114,900.00
88,800.00
89,100.00
80,400.00
Net Income from Continuing Operation Net Minority Interest
427,200.00
427,200.00
296,600.00
277,100.00
157,800.00
Total Unusual Items Excluding Goodwill
71,300.00
71,300.00
-29,300.00
-14,500.00
-24,500.00
Total Unusual Items
71,300.00
71,300.00
-29,300.00
-14,500.00
-24,500.00
Normalized EBITDA
604,200.00
604,200.00
548,100.00
511,500.00
345,100.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
15,400.80
15,400.80
-8,233.30
-4,161.50
-6,982.50
12/31/2020 - 8/4/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BIO Bio-Rad Laboratories, Inc.
279.04
-2.19%
 
CNMD CONMED Corporation
71.54
+0.32%
 
INSP Inspire Medical Systems, Inc.
235.44
+0.65%
 
IART Integra LifeSciences Holdings Corporation
28.89
-1.67%
 
QDEL QuidelOrtho Corporation
39.50
-2.24%
 
EW Edwards Lifesciences Corporation
88.27
+0.59%
 
NARI Inari Medical, Inc.
39.00
+5.09%
 
CTKB Cytek Biosciences, Inc.
5.74
-1.29%
 
PODD Insulet Corporation
168.00
+0.44%
 
QTRX Quanterix Corporation
15.47
-3.91%